Lantern Pharma Newsletter June 2022

Clinical Trial Preparations Update: The Harmonic trial is on schedule for a Summer 2022 launch. Lantern is finalizing revisions of the protocol amendment to the IND with the FDA - these are anticipated to be completed by the end of June. Lantern is currently in the process of contracting clinical trial sites for patient enrollment and is targeting a total of 15-20 sites to reach enrollment of 90 patients in the US.

‍
In a previous Phase 3 clinical trial, when LP-300 was administered with chemotherapy in a subset of never-smoker non-small cell lung cancer (NSCLC) patients, there was an increase in overall and 2-year patient survival by 91% and 125%, respectively, compared to chemotherapy alone. Additionally, LP-300 has been well tolerated in over 1,000 people.

‍
Why it matters: Lung cancer is the #1 cause of cancer deaths in the US and never-smokers with NSCLC are estimated to account for 15-20% of these deaths. NSCLC in never-smokers can be genetically different from lung cancer in smokers and patients may benefit from new therapies like LP-300 with chemotherapy.

‍

New Promising Preclinical Results for LP-284: Lantern conducted a study implanting mice with mantle cell lymphoma (MCL) xenografts and treating them with either LP-284 at 2 mg/kg or 4mg/kg, Bortezomib at 1 mg/kg, Ibrutinib at 50mg/kg, or Saline as a control.

• Mice treated with LP-284 at 4 mg/kg resulted in complete tumor regression at Day 13 (Left Graph).
• Additionally, mice treated with LP-284 at 2 mg/kg or 4 mg/kg resulted in greater tumor regression than Ibrutinib or Bortezomib, two current standard of care (SOC) agents to treat MCL (Left Graph).
• LP-284 (4 mg/kg) was also given to a subset of mice who had received either Bortezomib or Ibrutinib and still had tumor growth. Administering LP-284 to these mice resulted in significant regression of tumor growth by 95% for Bortezomib treated mice and 77% for Ibrutinib treated mice (Right Graph).

This study is still ongoing and final results will be available in the coming months.

‍
Why it matters: MCL is an aggressive subtype of B-cell non-Hodgkins Lymphoma that is typically diagnosed in advanced stages and has a low 2-5 year median patient survival.

• In the US an estimated 5,600 people are diagnosed with MCL per year and annually there are 1,400 deaths attributable to MCL.
• The first and second line standard of care agents, including Ibrutinib and Bortezomib, to treat MCL rarely achieve cures and have a high percentage of relapse and resistance.

The positive preclinical results for LP-284, in vitro and in vivo, suggest that LP-284 has the potential to fill the treatment void for MCL patients, who often lack effective treatment options.

‍

Dr. Maccecchini has over 30 years of biopharmaceutical experience in the development of novel therapies for Alzheimer's, Parkinson's, and other neurodegenerative diseases. She is the founder of Annovis Bio. (Nasdaq: ANVS), a company dedicated to treating neurodegenerative conditions, and has served as its President, Chief Executive Officer, and Director since 2008.

‍
Dr. Maccecchini was elected along with five existing Directors at Lantern's Annual Meeting of Stockholders held on June 8, 2022.

‍

Lantern hosted a KOL webinar on GBM and LP-184 for the potential treatment of GBM in May, which was Brain Tumor Awareness Month. The webinar featured two leading experts for the
treatment of glioblastoma - John Laterra, MD, PhD and Matthias Holdhoff, MD, PhD from The Johns Hopkins University School of Medicine - as well as Lantern’s Chief Scientific Officer, Kishor Bhatia, PhD.

‍
Why it matters: Every year, 13,000 people in the US are diagnosed with GBM and patients have a low 15-month median survival with treatment. In preclinical studies, LP-184 has shown nanomolar potency against GBM in vitro and in vivo, and crosses the blood brain barrier. LP- 184 has the potential to become a new line of therapy for GBM where there is an urgent and unmet clinical need.

If you missed the webinar, watch the replay here:
https://us06web.zoom.us/rec/share/cwxZFeZMxdXlL4sIDbY6ek_URTb9w11wYiPiy-ABnSW-TWvNXBB9XXvYmJVHowZB.0XQyNfs-hYrY5xkQ?
startTime=1653580571000

‍

This week, Panna Sharma, Lantern’s CEO & President, spoke at the LD Micro Invitational XII in Westlake Village, CA on June 7th, 2022. Find more info here: https://ldinv12.mysequire.com

‍
Panna will be speaking at the MedInvest Oncology Investor Conference on June 28th and 29th, 2022 in midtown Manhattan. Register here: https://www.medinvestconferences.com/register
‍

Additionally, Panna will be speaking at the World Orphan Drug Congress USA 2022 in Boston, MA on July 11-13, 2022.

Register here: https://secure.terrapinn.com/V5/step1.aspx?E=10568&p=1

‍